Difference between revisions of "Ivermectin has beneficial effects against SARS-COV-2"

Revision as of 23:49, 22 January 2022

Ivermectin has beneficial effects against SARS-COV-2 is an argument derived from over 76 independent studies conducted by researchers around the world showing an unambiguous medical benefit in the treatment of patients suffering from SARS-COV-2 infection and the resultant Covid-19 disease.

Reasons & Support 1) Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome).

2) Meta analysis using the most serious outcome shows 66% [53‑75%] and 83% [74‑89%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (excluding all GMK/BBC team studies), for primary outcomes, for peer-reviewed studies, and for RCTs.

3) Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.

<tbody>

</tbody>

Results	Studies	<a class="metal" href="#fig_fp">Prophylaxis</a>	<a class="metal" href="#fig_fp">Early treatment</a>	<a class="metal" href="#fig_fp">Late treatment</a>	Patients	Authors
<a class="metal" href="#fig_fp">All studies</a>	76	83% [74‑89%]	66% [53‑75%]	39% [23‑52%]	57,647	718
<a class="metal" href="#fig_fpp">Peer-reviewed</a><a class="metal" href="#fig_fpp">Peer-reviewed</a>	55	83% [73‑90%]	68% [50‑80%]	41% [17‑58%]	25,228	558
<a class="metal" href="#bbc">With GMK/BBC exclusions</a><a class="metal" href="#bbc">w/GMK/BBC exclusions</a>	51	82% [68‑89%]	73% [64‑80%]	53% [29‑69%]	44,741	545
<a class="metal" href="#fig_fpr">Randomized Controlled Trials</a><a class="metal" href="#fig_fpr">RCTs</a>	32	84% [25‑96%]	62% [45‑74%]	23% [-1‑41%]	7,032	361
<a class="metal" href="/supp.html#fig_fpre">RCTs w/GMK/BBC exclusions</a><a class="metal" href="/supp.html#fig_fpre">RCTs w/GMK/BBC exc.</a>	25	84% [25‑96%]	69% [56‑77%]	26% [-2‑46%]	4,423	299
Percentage improvement with ivermectin treatment

Claim
Statement of the claim	Ivermectin has beneficial effects against SARS-COV-2
Level of certainty	True
Nature	Factual
Counterclaim	Ivermectin has no effect or detrimental effects against SARS-COV-2
Dependent on	Definition:SARS-COV-2
Dependency of

References

[ivmmeta.com]

@@ Line 2: / Line 2: @@
 '''Reasons & Support'''
-@namespace svg url(http://www.w3.org/2000/svg); svg|a { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:visited { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:hover { text-decoration:underline; } .svgh:hover { text-decoration:underline; } @media only screen and (max-width:667px) { .annotation-text { font-weight:400; } } @font-face { font-family:'Roboto'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-regular.woff2') format('woff2'), url('/fonts/roboto-v27-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:500; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-500.woff2') format('woff2'), url('/fonts/roboto-v27-latin-500.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-700.woff2') format('woff2'), url('/fonts/roboto-v27-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:900; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-900.woff2') format('woff2'), url('/fonts/roboto-v27-latin-900.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-regular.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700italic.woff') format('woff'); } 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 65% 76 57,647 Improvement, Studies, Patients Relative Risk With exclusions 71% 51 44,741 Primary outcome 59% 76 57,700 Mortality 57% 37 44,932 Ventilation 46% 12 2,316 ICU admission 57% 7 21,857 Hospitalization 41% 20 11,380 Recovery 51% 24 3,866 Cases 78% 15 13,297 Viral clearance 57% 22 2,614 RCTs 57% 32 7,032 RCTs w/exc. 63% 25 4,423 Peer-reviewed 67% 55 25,228 Peer-rvw w/exc. 70% 41 21,188 Prophylaxis 83% 16 19,365 Early 66% 30 27,832 Late 39% 30 10,450 Ivermectin for COVID-19 ivmmeta.com Jan 22, 2022 Favors ivermectin Favors control
+) Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome).
-•Statistically significant improvements are seen for [mortality](#fig_fpd), [ventilation](#fig_fpm), [ICU admission](#fig_fpi), [hospitalization](#fig_fph), [recovery](#fig_fpry), [cases](#fig_fpc), and [viral clearance](#fig_fpv). All remain significant after [exclusions](https://ivmmeta.com/supp.html). 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome).
+) Meta analysis using the most serious outcome shows 66% [53‑75%] and 83% [74‑89%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (excluding all GMK/BBC team studies), for primary outcomes, for peer-reviewed studies, and for RCTs.
-•Meta analysis using the most serious outcome shows 66% \[53‑75%\] and 83% \[74‑89%\] improvement for [early treatment and prophylaxis](#fig_fpep), with similar results after [exclusion based sensitivity analysis](#fig_fpe) (excluding all GMK/BBC team studies), for [primary outcomes](https://ivmmeta.com/supp.html), for [peer-reviewed studies](#fig_fpp), and for [RCTs](#fig_fpr).
+) Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.
-•Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.
+<table class="tables">
+<tbody><tr><td>Results</td><td class="h350"><i>Studies</i></td>
+  <td><i><a class="metal" href="#fig_fp">Prophylaxis</a></i></td>
+  <td><i><a class="metal" href="#fig_fp">Early treatment</a></i></td>
+  <td><i><a class="metal" href="#fig_fp">Late treatment</a></i></td>
+  <td class="h375"><i>Patients<i></i></i></td><td class="h450"><i>Authors<i></i></i></td></tr>
-@namespace svg url(http://www.w3.org/2000/svg); svg|a { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:visited { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:hover { text-decoration:underline; } .svgh:hover { text-decoration:underline; } @media only screen and (max-width:667px) { .annotation-text { font-weight:400; } } @font-face { font-family:'Roboto'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-regular.woff2') format('woff2'), url('/fonts/roboto-v27-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:500; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-500.woff2') format('woff2'), url('/fonts/roboto-v27-latin-500.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-700.woff2') format('woff2'), url('/fonts/roboto-v27-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:900; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-900.woff2') format('woff2'), url('/fonts/roboto-v27-latin-900.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-regular.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700italic.woff') format('woff'); } 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 65% 76 57,647 Improvement, Studies, Patients Relative Risk With exclusions 71% 51 44,741 Primary outcome 59% 76 57,700 Mortality 57% 37 44,932 Ventilation 46% 12 2,316 ICU admission 57% 7 21,857 Hospitalization 41% 20 11,380 Recovery 51% 24 3,866 Cases 78% 15 13,297 Viral clearance 57% 22 2,614 RCTs 57% 32 7,032 RCTs w/exc. 63% 25 4,423 Peer-reviewed 67% 55 25,228 Peer-rvw w/exc. 70% 41 21,188 Prophylaxis 83% 16 19,365 Early 66% 30 27,832 Late 39% 30 10,450 Ivermectin for COVID-19 ivmmeta.com Jan 22, 2022 Favors ivermectin Favors control
+<tr><td><a class="metal" href="#fig_fp">All studies</a></td>
+<td class="h350">76</td>
+<td><b>83%</b>&nbsp;<span class="rrcls">[74‑89%]</span></td>
+<td><b>66%</b>&nbsp;<span class="rrcls">[53‑75%]</span></td>
+<td><b>39%</b>&nbsp;<span class="rrcls">[23‑52%]</span></td>
+<td class="h375">57,647</td>
+<td class="h450">718</td>
-•While [many treatments](https://c19early.com/) have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 25% of ivermectin studies show zero events in the treatment arm.
-•[Multiple treatments](https://c19early.com/) are typically used in combination, which may be significantly more effective.
+</tr><tr><td><span class="desktop"><a class="metal" href="#fig_fpp">Peer-reviewed</a></span><span class="mobile"><a class="metal" href="#fig_fpp">Peer-reviewed</a></span></td>
+<td class="h350">55</td>
+<td><b>83%</b>&nbsp;<span class="rrcls">[73‑90%]</span></td>
+<td><b>68%</b>&nbsp;<span class="rrcls">[50‑80%]</span></td>
+<td><b>41%</b>&nbsp;<span class="rrcls">[17‑58%]</span></td>
+<td class="h375">25,228</td>
+<td class="h450">558</td>
-•Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used, including treatments, as supported by Pfizer \[[Pfizer](#ref_pfizerq22021), [TrialSiteNews](#ref_trialsitepfizer)\]. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.
-_Studies_
+</tr><tr><td><span class="desktop"><a class="metal" href="#bbc">With GMK/BBC exclusions</a></span><span class="mobile"><a class="metal" href="#bbc">w/GMK/BBC exclusions</a></span></td>
+<td class="h350">51</td>
+<td><b>82%</b>&nbsp;<span class="rrcls">[68‑89%]</span></td>
+<td><b>73%</b>&nbsp;<span class="rrcls">[64‑80%]</span></td>
+<td><b>53%</b>&nbsp;<span class="rrcls">[29‑69%]</span></td>
+<td class="h375">44,741</td>
+<td class="h450">545</td>
-_[Prophylaxis](#fig_fp)_
-_[Early treatment](#fig_fp)_
+</tr><tr><td><span class="desktop"><a class="metal" href="#fig_fpr">Randomized Controlled Trials</a></span><span class="mobile"><a class="metal" href="#fig_fpr">RCTs</a></span></td>
+<td class="h350">32</td>
+<td><b>84%</b>&nbsp;<span class="rrcls">[25‑96%]</span></td>
+<td><b>62%</b>&nbsp;<span class="rrcls">[45‑74%]</span></td>
+<td><b>23%</b>&nbsp;<span class="rrcls">[-1‑41%]</span></td>
+<td class="h375">7,032</td>
+<td class="h450">361</td>
-_[Late treatment](#fig_fp)_
-_Patients_
+</tr><tr><td><span class="desktop"><a class="metal" href="/supp.html#fig_fpre">RCTs w/GMK/BBC exclusions</a></span><span class="mobile"><a class="metal" href="/supp.html#fig_fpre">RCTs w/GMK/BBC exc.</a></span></td>
+<td class="h350">25</td>
+<td><b>84%</b>&nbsp;<span class="rrcls">[25‑96%]</span></td>
+<td><b>69%</b>&nbsp;<span class="rrcls">[56‑77%]</span></td>
+<td><b>26%</b>&nbsp;<span class="rrcls">[-2‑46%]</span></td>
+<td class="h375">4,423</td>
+<td class="h450">299</td>
-_Authors_
+</tr><tr class="nob"><td class="nob" colspan="7"><i>Percentage improvement with ivermectin treatment</i></td></tr>
+</tbody></table>
-[All studies](#fig_fp)
-**83%** \[74‑89%\]
-**66%** \[53‑75%\]
-**39%** \[23‑52%\]
-,647
-[Peer-reviewed](#fig_fpp)[Peer-reviewed](#fig_fpp)
-**83%** \[73‑90%\]
-**68%** \[50‑80%\]
-**41%** \[17‑58%\]
-,228
-[With GMK/BBC exclusions](#bbc)[w/GMK/BBC exclusions](#bbc)
-**82%** \[68‑89%\]
-**73%** \[64‑80%\]
-**53%** \[29‑69%\]
-,741
-[Randomized Controlled Trials](#fig_fpr)[RCTs](#fig_fpr)
-**84%** \[25‑96%\]
-**62%** \[45‑74%\]
-**23%** \[-1‑41%\]
-,032
-[RCTs w/GMK/BBC exclusions](/supp.html#fig_fpre)[RCTs w/GMK/BBC exc.](/supp.html#fig_fpre)
-**84%** \[25‑96%\]
-**69%** \[56‑77%\]
-**26%** \[-2‑46%\]
-,423
-_Percentage improvement with ivermectin treatment_
-•There is evidence of a negative publication bias, and the probability that an ineffective treatment generated results as positive as the 76 studies is estimated to be 1 in 68 billion.
-•[Over 20 countries](https://ivmstatus.com/) have adopted ivermectin for COVID-19. The evidence base is [much larger](#table_whoapproval) and has much lower conflict of interest than typically used to approve drugs.
-•All data to reproduce this paper and sources are in the [appendix](#appendix_methods). See \[[Bryant](#ref_bryant), [Hariyanto](#ref_hariyanto2), [Kory](#ref_kory3), [Lawrie](#ref_lawrie), [Nardelli](#ref_nardelli)\] for other meta analyses with similar results confirming efficacy.
-[@namespace svg url(http://www.w3.org/2000/svg); svg|a { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:visited { color:#606060; /\* lc \*/ fill:#606060; /\* lc \*/ } svg|a:hover { text-decoration:underline; } .svgh:hover { text-decoration:underline; } @media only screen and (max-width:667px) { .annotation-text { font-weight:400; } } @font-face { font-family:'Roboto'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-regular.woff2') format('woff2'), url('/fonts/roboto-v27-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-italic.woff2') format('woff2'), url('/fonts/roboto-v27-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:500; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-500.woff2') format('woff2'), url('/fonts/roboto-v27-latin-500.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-700.woff2') format('woff2'), url('/fonts/roboto-v27-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto'; font-style:normal; font-weight:900; font-display:swap; src:local(''), url('/fonts/roboto-v27-latin-900.woff2') format('woff2'), url('/fonts/roboto-v27-latin-900.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-regular.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-regular.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:300; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-300italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-300italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:400; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-italic.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:normal; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700.woff') format('woff'); } @font-face { font-family:'Roboto Condensed'; font-style:italic; font-weight:700; font-display:swap; src:local(''), url('/fonts/roboto-condensed-v19-latin-700italic.woff2') format('woff2'), url('/fonts/roboto-condensed-v19-latin-700italic.woff') format('woff'); } 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kory et al. 69% 0.31 \[0.20-0.47\] Improvement, RR \[CI\] Bryant et al. 62% 0.38 \[0.19-0.73\] Lawrie et al. 83% 0.17 \[0.08-0.35\] Nardelli et al. 79% 0.21 \[0.11-0.36\] Hariyanto et al. 69% 0.31 \[0.15-0.62\] WHO (OR) 81% 0.19 \[0.09-0.36\] ivmmeta 57% 0.43 \[0.32-0.57\] Ivermectin meta analysis mortality results ivmmeta.com Jan 22, 2022 Favors ivermectin Favors control](#fig_metam)
-[Global adoption: 37%](https://ivmstatus.com/)
-[![](plot/ivmworld.svg)](https://ivmstatus.com/)
-_Evidence base used for other COVID-19 approvals_
-Medication
-Studies
-Patients
-Improvement
-[Molnupiravir (UK)](https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra)
-%
-[Budesonide (UK)](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/04/C1253-interim-position-statement-inhaled-budesonide-for-adults.pdf)
-,779
-%
-[Remdesivir (USA EUA)](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment)
-,063
-%
-[Casirivimab/i.. (USA EUA)](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19)
-%
-_Ivermectin evidence_
-,623
-% \[57‑72%\]
 {{Claim
@@ Line 175: / Line 73: @@
 ==References==
 <references/>
-ivmmeta.com
+[[https://ivmmeta.com/ ivmmeta.com]]
 [[Category:Biology and Medicine]]

Difference between revisions of "Ivermectin has beneficial effects against SARS-COV-2"

Revision as of 23:49, 22 January 2022

References

Navigation menu

Search